Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Anti-HER2 Therapy in Early HER2-Positive Breast Cancer (Biological Phase)
2008-005466-30Phase 3Unknown
- Sponsor
- The University of Manchester
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of lapatinib and trastuzumab in breast cancer, sponsored by The University of Manchester. Primary endpoints: Change in tumor apoptosis between baseline biopsy and surgery and Change in tumor proliferation between baseline biopsy and surgery. Status: unknown.
02
Drugs
lapatinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-005466-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005466-30.